Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haojun Ouyang

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Chemical Information and Computer Sciences|September 23, 2003
Predictive toxicology: benchmarking molecular descriptors and statistical methodsJun Feng, Laura Lurati, Haojun Ouyang, et al.
Alcoholism, Clinical and Experimental Research|September 10, 2013
A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependenceConrad J Wong, Jennifer Witcher, Craig Mallinckrodt, et al.
The Lancet. Neurology|September 18, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trialEugenio Mercuri, Francesco Muntoni, Giovanni Baranello, et al.
Investigational New Drugs|September 18, 2015
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumorsSandrine J Faivre, Anthony J Olszanski, Karin Weigang-Köhler, et al.
The Lancet. Neurology|March 20, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trialJohn W Day, Richard S Finkel, Claudia A Chiriboga, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Chemical Information and Computer Sciences|September 23, 2003
Predictive toxicology: benchmarking molecular descriptors and statistical methodsJun Feng, Laura Lurati, Haojun Ouyang, et al.
Alcoholism, Clinical and Experimental Research|September 10, 2013
A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependenceConrad J Wong, Jennifer Witcher, Craig Mallinckrodt, et al.
The Lancet. Neurology|September 18, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trialEugenio Mercuri, Francesco Muntoni, Giovanni Baranello, et al.
Investigational New Drugs|September 18, 2015
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumorsSandrine J Faivre, Anthony J Olszanski, Karin Weigang-Köhler, et al.
The Lancet. Neurology|March 20, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trialJohn W Day, Richard S Finkel, Claudia A Chiriboga, et al.
Pageof 1